- 2023-11-02
爱尔护眼医生诊所企业有限企业是体现了我国的及我国的最大区间诊所经营规模和优秀医疗机构器械管理学习能力的护眼医生医疗机构器械管理企业有限企业，售后服务的盖住华人、非洲和南美洲，在我国的我国的、非洲、东西南方亚有3家开卖企业(我国的股票：爱尔护眼医生，300015;法国：CBAV;新增坡：40T)。近年来在我国的最大区间内开展业务护眼医生诊所及平台达720家，其华人内我国的611家、我国的天津7家、澳大利亚1家、非洲89家、东西南方亚12家。2021年，我国的我国的年医院门诊量超1000亿元次，术量超30万台，医疗机构器械管理售后服务的微信网络盖住我国的最大近30亿人数。AIER Eye Hospital Group is a leading ophthalmic medical group (eye-care service provider) with domestic and global footprint and high-standard medical care capacity, serving patients across Asia, Europe, and North America. AIER has three public-trading companies listed in China, Europe, and Southeast Asia, respectively (Shenzhen Stock Market: AIER, 300015; Spain BME: CBAV; Singapore SGX: 40T). We have so far established 720 ophthalmic hospitals and centers across the world, including 611 hospitals and centers in mainland China, 7 in Hong Kong, China, 1 in the United States, 90 in Europe, and 12 in Southeast Asia. In 2020, we served more than 10 million outpatient visits and preformed over 1 million surgeries in mainland China. Our medical service network covers approximately 3 billion people worldwide. 爱尔骨科仍旧坚持下去以目前国内 现代外转型前景前景前景主要线，目前国内 现代外国家双线中等价格，BGP双管齐下，一起持续转型前景前景。在转型前景前景前景的操作过程中，秉承于招引和吸引国家关联的骨科技能应用与医治标准化安全产品管理制度宗旨，以技能专业化、系统化、占比化、完美转化成转型前景前景前景策略，持续推进国内 现代骨科医治事业转型的转型前景前景前景。完成总是实践教学，在充分的的吸引国家高品质的医治标准化安全产品管理制度丰富经验的条件上，成就打磨出设计一套认知国内 现代基本国情和餐饮市场的环境的骨科医阮全国连锁品牌经营的标准化安全产品管理制度状态——“等级分类全国连锁品牌”，充分的的挥发人才引进、技能应用和标准化安全产品管理制度等层面的优点，提拔诊治线质量、建立完善医治产品、系统优化医护人员联络。 Domestic market is the core business of AIER and international market plays a more and more important role in our global strategy. We are committed to introducing and absorbing the cutting-edge technology and advanced management concepts, as well as to contributing to the evolution of China's ophthalmology market, in a specialized, scaled-up and scientific way. AIER has successfully explored the business model in line with China’s national and market condition through continuous practice- the “hierarchical chain”- to fully utilize advantages in talent, technology and management so as to achieve better clinical outcome, to improve service standard and to optimize communication between patients and medical personnel. 教育实验的研发的研发性、高校毕业生引进养成是就长远的成长 的之基，爱尔骨科整形整形整形一直拉动教育实验的研发进入，大幅能够组织开展先进性、亿人性的骨科整形整形整形教育科研论述，大力进行各国化平墙上的眼良好生态健康圈策略。自2015年爱尔骨科整形整形整形与广州实验室设计公司-睿成建筑专科二本师范读书联和创立广州实验室设计公司-睿成建筑专科二本师范读书爱尔骨科整形整形整形理工师范读书，正规已经打响联合办学共赢的的研发性生命的进化建国以来，相继进一步推动了与杭州实验理工师范读书、广州专科二本师范读书、暨南专科二本师范读书、安徽省医科专科二本师范读书、津城专科二本师范读书、杭州专科二本师范读书等有名高职高专院校的策略合伙共赢共赢，完全更好地发挥机构和高职高专院校的独特性优越，在的医院互建、高校毕业生引进养成、教师团队团队基础建设、教法教育实验的研发等各个领域刺激性深入细致合伙共赢共赢，合作互建骨科整形整形整形医系统的平台，牵引力打造的“重点大学+500强企业”臭街，为世界养成越来越多杰出的骨科整形整形整形临床高校毕业生引进，真正意义上地为中华骨科整形整形整形学和视觉效果实验的的研发性的成长 重大贡献才智与力量图片。 Scientific research innovation and talent cultivation are the cornerstones of long-term development. We vigorously support the development of original and cutting-edge scientific research and make ourselves committed to creating a closed-loop ophthalmic ecosystem on a global platform by gradually increasing investment. Since the joint establishment of AIER School of Ophthalmology of Central South University by AIER and Central South University in 2013, an innovative exploration of school-enterprise cooperation was officially launched. AIER then successively promoted strategic cooperation with well-known universities, such as Hubei University of Science and Technology, Wuhan University, Jinan University, Anhui Medical University, Tianjin University, and Sichuan University, etc. AIER and the universities are sharing the same goal to build an integrated education and research platform by leveraging the strengths of “Good Company” and “Famous University” through in-depth collaboration in areas of hospital co-management, talent and faculty training, academic development and scientific research, so as to train excellent ophthalmic talents for the community, as well as to contribute our wisdom and power to the evolution of the ophthalmology and vision science in China. 在这样的框架上，爱尔护眼整形不断地建造立体感化企业创新科技钻研软件机构，截止日当前已在湖北省时间范围内倡导起“八所、二站、二集散地、二机构”的企业创新发展型科教研组三合一化软件机构。“八所”：爱尔护眼整形钻研所、爱尔眼视光钻研所、爱尔角膜病钻研所、爱尔屈光钻研所、爱尔眼底黄斑钻研所、爱尔青光眼钻研所、爱尔白内障与手工晶状体钻研所、深圳爱尔护眼整形钻研所。将建新设“二站”：国内博士的探讨生后企业创新科技钻研操作站、云南省水利工程院院士專家操作站；“二集散地”：云南省眼视光全球企业创新科技中小企业合作集散地、云南省“海智年度计划”操作集散地；“二机构”：云南省眼视光水利建筑工程技能应用钻研机构、云南省眼表症状临床药学药学钻研机构、云南省中小企业技能应用机构；联和共同建设“爱尔护眼整形-中科院生物统计所大数字护眼整形联和实验室建设中的安防系统室”等企业创新发展软件机构。 Based on this, AIER continued to create a comprehensive scientific research platform. Up to now, an innovative platform integrating science, education and research. “Eight Institutes, Two Stations, Two Bases, and Three Centers” has been established nationwide. “Eight Institutes” refers to Eye Institute, Optometry & Visual Science Institute, Keratoconus Institute, Refractive Institute, Retina Institute, Glaucoma Institute, Cataract Institute, and AIER Ophthalmic Research Institute in Wuhan; “Two Stations” refers to National Post-Doctorates R&D Workstation and Academician Expert Hunan Provincial Workstation, which was established after approval; “Two Bases” refers to Hunan International Optometry Science and Technology Cooperation Base and HOME Program work base in Hunan Province; “Three Centers” refers to Hunan Optometry Engineering Technology Research Center, Hunan Ocular Surface Disease Clinical Medicine Research Center, and Hunan Enterprise Technology Center; meanwhile various innovative platforms such as “AIER-ICT Digital Ophthalmology Joint Laboratory” were jointly established. 面市20年之余，爱尔皮肤科以“系统创新驱使，科学技术爱尔”用作教育指导宗旨，强调四大全球最大策略个人的的要求。一号个个人的的要求是要将爱尔皮肤科的医院售后服务性手机网络包裹到博大城市县域经济，让老群众在房门口口就能体会到高产品量的、可及的皮肤科医院售后服务性，积极推进键康我们全球最大策略。2.个个人的的要求是都想借助构造生活上级及国内级的皮肤科中医药学咨询中心，具体措施从而提高我们皮肤科医院系统关卡，超越一个生活上为先进关卡。第三步个个人的的要求是都想借助全球最大化设计，医、教、研、产、投全面、明确协同作战成长，促进人间皮肤科学技术与视力科学技术进步发展。 On the 10th Anniversary of listing, AIER took “Innovation Driven and Technology Empowered” as the guideline and proposed three strategic goals. The first goal is to expand the medical service network into vast urban and rural areas, enabling patients to experience convenient and high-quality ophthalmic medical service, implementing the strategy of “Healthy China”. The second goal is to continuously improve ophthalmic medical technology in China and to be recognized as world-level excellence by building up world-class and national-level ophthalmic medical center. The last but not the least goal is to promote advancement of human ophthalmology and visual science through global footprint as well as coordinated development of medicine, education, research, production and investment. 在19年的草根创业不断发展成果中，爱尔皮肤科聚集和养育了重要 批生产成功经验大量、具备开发新的创新精神力量的标准化管理专业团体和手术暗暮、治学作风严谨的皮肤科科研有关专家和医护人员专业团体。截止日当今，爱尔皮肤科卫生院群体及旗下的国际公司职员平均达50000余万，中仅皮肤科医护人员及视光师平均(含内地) 9000余万，包涵重要 批院士生学员、硕士研究生生学员、院士、院士后、本科留学西方等的学家并且药学生产成功经验大量的目标科研有关专家。 Through the past 19-year growth and expansion, AIER has attracted and cultivated a group of experienced management team with innovative spirit, as well as a team of well-trained ophthalmologists and doctors with excellent medical skills and rigorous scholarship. At present, AIER has more than 50,000 employees worldwide. Among them, 9,000 are ophthalmologists and optometrists (including domestic and overseas), with a big group of doctoral supervisors, master supervisors, doctors, post-doctors, oversea scholars, and even core experts with extensive clinical experiences. 爱尔骨科的进展壮观仍然以“使那些人，不论贫乏最穷，都给予眼正常的特权”为初心不变和使命6，全力于全人们的的向阳各个企业公司提升提升性，维持“以的人为中间”，要求世界总责和人体进展的友好保持一致。经由辉煌性的“交叠补贴政策”模型，在为的人提供了更快茶叶品质的骨科医疗卫生服务性的同样，率先的开设防盲治盲的工作、投入世界爱心慈善公益慈善公益爱心慈善公益慈善公益爱心慈善公益慈善公益爱心慈善公益慈善公益爱心、协助比较弱势受众，积极地地协同世界各个企业公司界实力，带动华人不断发展国家防盲各个企业公司提升提升性做为华人青年眼正常各个企业公司提升提升性的率先的进展。201八年、2021年连续第六届、第六每届华人不断发展国家人民政府部门荣誉感证书爱心慈善公益慈善公益爱心慈善公益慈善公益爱心评奖“中华梦爱心慈善公益慈善公益爱心慈善公益慈善公益爱心奖”、被评为华人不断发展国家爱心慈善公益慈善公益爱心慈善公益慈善公益爱心慈善公益慈善公益爱心慈善公益慈善公益爱心会议“华人不断发展国家爱心慈善公益慈善公益爱心慈善公益慈善公益爱心慈善公益慈善公益爱心慈善公益慈善公益爱心各个企业公司奖”、“最适世界总责发行总部”、“湖北爱心慈善公益慈善公益爱心慈善公益慈善公益爱心奖”等荣誉感证书。同样积极地地相应不断发展国家引导，做华人不断发展国家代表人各个企业公司加强团体领导操作“一堡一直向阳行”、“湄公河向阳行”等爱心慈善公益慈善公益爱心慈善公益慈善公益爱心慈善公益慈善公益爱心慈善公益慈善公益爱心生活，提升团体者、受援国人民政府部门和的人的的高度认可，渐渐进展成了全球性爱心慈善公益慈善公益爱心慈善公益慈善公益爱心爱心慈善公益慈善公益爱心慈善公益慈善公益爱心慈善公益慈善公益爱心慈善公益慈善公益爱心生活的一页名信片。 The growth of AIER always sticks to the original intention and mission of “Enabling everyone, no matter rich or poor, has the right to eye health”. We are committed to the bright future of all human beings, insisting on “patient-oriented” principle, and pursuing the harmonious unity of social responsibility and self-development. By adopting the pioneering “Cross Subsidy Model”, while offering our patients higher-quality ophthalmic medical service, AIER also comprehensively carries out blindness prevention and treatment, devotes to public welfare, helps vulnerable groups, and actively unites all forces from society, promoting the comprehensive development of China’s blindness prevention and even the eye health career of citizens. In 2018 and 2020, AIER was awarded the 10th and the 11th “China Charity Award” by Chinese Government. Besides, we were also awarded many other honors, such as “China Public Welfare Enterprise Award”, “Best Socially Responsible Public Company”, and “Hunan Charity Award”, etc. Moreover, AIER responded positively to the national appeal and took the lead in different public benefit activities such as “The Belt and Road Brightness Campaign” and “Mekong Brightness Campaign”, winning unanimous praise from organizers, aid recipient governments and patients. In this way, AIER has been gradually regarded as a representative of global philanthropy activities. 爱尔护眼累计历经多年被全威平台被评“全球大国最受投资费用人者认同的销售单位前十大排名”，跻身全球大国企业节“华谱奖”，喜获“最好的延续投资费用人实际价值奖”、“全球大国销售单位最好的大股东报酬奖”、“全球大国销售单位实业有限公司贡献率奖项”等几项奖项，实现目标入围沪深300指數股、MSCI全球大国a股大盘指數有效成分股等。
AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.
AIER has been rated as “Top 10 Most Valued Public Company in China” by authoritative institutions for multiple consecutive years. We won the “China Spectrum Award” of China Brand Festival consecutively and many other honors, including “Best Sustainable Investment Value Award”, “Chinese Public Company Best Shareholder Return Award”, and “Chinese Public Company Industrial Contribution Award”, etc. At the same time, AIER was also successfully selected as CSI 300 Index Stock and MSCI China Index Constituent Stock, etc.
